Modulation of the Therapeutic Resistance in SK-MEL-24 Human Melanoma Cells by Combined Treatments
Source abstract
Abstract
Melanoma represents a worldwide public health problem due to its high incidence and mortality rates. Despite the advances in melanoma therapy, not all patients respond to single or combined therapy because of primary or acquired resistance to the anti-tumor agents. Recently, positive results have been reported since the specific monoclonal antibodies, such as Ipilimumab (Ipi) and Nivolumab (Niv), were included in therapeutic protocols as immune checkpoint inhibitors. The evolution of neoplastic diseases and the therapeutic approaches in cancer involve several biological processes, including apoptosis, DNA progression through cell cycle phases, the release of pro-inflammatory cytokines, and changes in the expression of melanoma genes. Therefore, the potential modulation of these processes and associated molecules, due to single or combined treatments with oncolytic drugs like Carboplatin and Paclitaxel, checkpoint inhibitors such as Ipi and Niv, or natural bioactive compounds like Resveratrol or Quercetin, could represent a great benefit in melanoma treatment, contributing to the decrease or even reversal of the drug resistance in melanoma cells.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Click Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Carcinogenesis and Molecular Biology Department, Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, 022328 Bucharest, Romania
Cancer Biology Department, Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, 022328 Bucharest, Romania
Center of Immunology, “Stefan S. Nicolau” Institute of Virology, Romanian Academy, 030304 Bucharest, Romania
Faculty of Pharmacy, Titu Maiorescu University, 040314 Bucharest, Romania
Department of Biochemistry and Biophysics, Faculty of Midwives and Nursing, University of Medicine and Pharmacy Carol Davila Bucharest, 050474 Bucharest, Romania
References (56)
Show source-provided references
1. Global burden of cutaneous melanoma in 2020 and projections to 204010.1001/jamadermatol.2022.0160 ↗
2. Waseh, S., and Lee, J.B. (2023). Advances in melanoma: Epidemiology, diagnosis, and prognosis. Front. Med., 10.10.3389/fmed.2023.1268479 ↗
3. Update in genetic susceptibility in melanoma
4. Melanoma risk factors and prevention10.1016/j.cps.2021.05.001 ↗
5. Ultraviolet radiation-mediated development of cutaneous melanoma: An update10.1016/j.jphotobiol.2018.06.005 ↗
6. Conforti, C., and Zalaudek, I. (2021). Epidemiology and Risk Factors of Melanoma: A Review. Dermatol. Pract. Concept., 11.10.5826/dpc.11S1a161S ↗
7. Sorino, C., Iezzi, S., Ciuffreda, L., and Falcone, I. (2024). Immunotherapy in melanoma: Advances, pitfalls, and future perspectives. Front. Mol. Biosci., 11.10.3389/fmolb.2024.1403021 ↗
8. Wang, X., Ma, S., Zhu, S., Zhu, L., and Guo, W. (2025). Advances in immunotherapy and targeted therapy of malignant melanoma. Biomedicines, 13.10.3390/biomedicines13010225 ↗
9. Advances in targeted therapy and immunotherapy for melanoma10.3892/etm.2023.12115 ↗
10. Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Review Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.10.3390/cancers15041106 ↗
11. Fernandez, M.F., Choi, J., and Sosman, J. (2023). New approaches to targeted therapy in melanoma. Cancers, 15.10.3390/cancers15123224 ↗
12. Thornton, J., Chhabra, G., Singh, C.K., Guzman-Perez, G., Shirley, C.A., and Ahmad, N. (2022). Mechanisms of immunotherapy resistance in cutaneous melanoma: Recognizing a shapeshifter. Front. Oncol., 12.10.3389/fonc.2022.880876 ↗
13. Long-term toxici-ties of immune checkpoint inhibitor (ICI) in melanoma patients10.3390/curroncol29100629 ↗
14. Toxicity management of immunotherapy for patients with metastatic melanoma10.21037/atm.2016.07.10 ↗
15. Immunological effects of conventional chemotherapy and targeted anticancer agents10.1016/j.ccell.2015.10.012 ↗
16. Melanoma treatment in review10.2147/ITT.S134842 ↗
17. Bailly, C., Thuru, X., and Quesnel, B. (2020). Combined cytotoxic chemotherapy and immunotherapy of cancer: Modern times. NAR Cancer, 2.10.1093/narcan/zcaa002 ↗
18. Rašková, M., Lacina, L., Kejík, Z., Venhauerová, A., Skaličková, M., Kolář, M., Jakubek, M., Rosel, D., Smetana, K., and Brábek, J. (2022). The role of IL-6 in cancer cell invasiveness and metastasis-overview and therapeutic opportunities. Cells, 11.10.3390/cells11223698 ↗
19. Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment10.1016/j.coi.2023.102409 ↗
20. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model10.1111/jog.13521 ↗
21. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles10.1038/s41388-018-0581-9 ↗
22. Taxol: An antimitotic agent with a new mechanism of action10.1016/0163-7258(84)90025-1 ↗
23. Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis10.1016/j.biopha.2016.08.047 ↗
24. Ko, J.H., Sethi, G., Um, J.Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A., and Ahn, K.S. (2017). The role of Resveratrol in cancer therapy. Int. J. Mol. Sci., 18.10.3390/ijms18122589 ↗
25. Real-time analysis of quercetin, resveratrol and/or doxorubicin effects in MCF-7 cells
26. Rodrigo, L. (2016). Chapter Modulation of Apoptosis in Colon Cancer Cells by Bioactive Compounds. Colorectal Cancer—From Pathogenesis to Treatment, Intech.10.5772/61359 ↗
27. Genistein potentiates the apoptotic effect of 5-fluorouracyl in colon cancer cell lines
28. Modulation of the interplay between p53, ICAM-1 and VEGF in drug-treated LoVo colon cancer cells10.25083/rbl/24.2/261.270 ↗
29. Mihaila, M., Hotnog, C.M., Bostan, M., Munteanu, A.C., Vacaroiu, I.A., Brasoveanu, L.I., and Uivarosi, V. (2021). Anticancer Activity of Some Ruthenium (III) Complexes with Quinolone Antibiotics: In vitro cytotoxicity, cell cycle modulation, and apoptosis-inducing properties in LoVo colon cancer cell line. Appl. Sci., 11.10.3390/app11188594 ↗
30. Role of p38-mitogen-activated protein kinase in modulation of the response to therapy in FaDu human pharyngeal carcinoma cell line10.25083/rbl/24.1/118.128 ↗
31. Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases
32. Bolovan, L.M., Ceausu, M., Stanciu, A.E., Panait, M.E., Busca, A., Hotnog, C.M., Bleotu, C., Gales, L.N., Georgescu, M.T., and Prunoiu, V.M. (2023). Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma. J. Pers. Med., 13.10.3390/jpm13060898 ↗
33. Bolovan, L.M., Panait, M.E., Busca, A., Stanciu, A.E., Chiriac, D., Mihalcea, C.E., Hotnog, C.M., Georgescu, M.T., Voinea, S.C., and Prunoiu, V.M. (2025). Variation in immune and inflammatory blood markers in advanced melanoma patients treated with PD-1 inhibitors: A preliminary exploratory study. Biomedicines, 13.10.3390/biomedicines13061378 ↗
34. Albulescu, A., Botezatu, A., Fudulu, A., Hotnog, C.M., Bostan, M., Mihaila, M., Iancu, I.V., Plesa, A., and Brasoveanu, L. (2025). Combined effect of conventional chemotherapy with epigenetic modulators on glioblastoma. Genes, 16.10.3390/genes16020138 ↗
35. Differential Expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells
36. In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells10.1007/s002620050557 ↗
37. Levels of membrane CD59 regulate the extent of complement—Mediated lysis of human melanoma cells
38. Strucure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)
39. Lowe, J., Shatz, M., Resnick, M.A., and Menendez, D. (2013). Modulation of immune responses by the tumor suppressor p53. BioDiscovery, 8.10.7750/BioDiscovery.2013.8.2 ↗
40. (2025, September 20). Available online: https://cancertools.org/cell-lines/sk-mel-24-161916/.
41. Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene10.3892/etm.2012.497 ↗
42. Cocos, F.-I., Anuta, V., Popa, L., Ghica, M.V., Nica, M.-A., Mihăilă, M., Fierăscu, R.C., Trică, B., Nicolae, C.A., and Dinu-Pirvu, C.-E. (2024). Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy. Pharmaceutics, 16.10.3390/pharmaceutics16070960 ↗
43. Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma10.7150/jca.27295 ↗
44. Al Hmada, Y., Brodell, R.T., Kharouf, N., Flanagan, T.W., Alamodi, A.A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haikel, Y., and Megahed, M. (2024). Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells. Cancers, 16.10.3390/cancers16020470 ↗
45. Ziebolz, B. (2010). Cutting Edge Technologies: Cell Analysis, Springer.
46. Maciuca, A.M., Munteanu, A.C., Mihaila, M., Badea, M., Olar, R., Nitulescu, G.M., Munteanu, C.V.A., Bostan, M., and Uivarosi, V. (2020). Rare-Earth Metal Complexes of the Antibacterial Drug Oxolinic Acid: Synthesis, Characterization, DNA/Protein Binding and Cytotoxicity Studies. Molecules, 25.10.3390/molecules25225418 ↗
47. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker10.1016/j.jid.2021.12.012 ↗
48. Mercogliano, M.F., Bruni, S., Mauro, F., Elizalde, P.V., and Schillaci, R. (2021). Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. Cancers, 13.10.3390/cancers13030564 ↗
49. Role of the androgen receptor in melanoma aggressiveness10.1038/s41419-025-07350-4 ↗
50. Lasalle, C., Wang, Y., Morales, M.T., Giubellino, A., Amber, K.T., and Mansini, A.P. (2025). Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications. Cancers, 17.10.20944/preprints202508.0198.v1 ↗
51. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?10.1016/j.pharmthera.2024.108613 ↗
52. Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab10.1080/2162402X.2024.2432723 ↗
53. Combining Immunotherapy and targeted therapies in cancer treatment10.1038/nrc3237 ↗
54. A review of cancer immunotherapy: From the past, to the present, to the future10.3747/co.27.5223 ↗
55. Toward a better understanding of the complexity of cancer drug resistance10.1146/annurev-pharmtox-010715-103111 ↗
56. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries